Active	Status	Sponsor type	Region	Phase	Filter
1 Active 4 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Myoconda (clarithromycin/clofazimine/rifabutin) / RedHill
2016-005199-90: Open Label Study to evaluate whether a fixed-dose of RHB-104 is safe and effective in subjects suffering from moderate to Severely Crohn’s disease.	Not yet recruiting	3	100	Europe	RHB-104, Capsule	RedHill Biopharma Ltd., RedHill Biopharma Ltd.	Moderately to Severely Active Crohn's Disease, Crohn's Disease, Diseases [C] - Digestive System Diseases [C06]